Orkambi®

Active substance

lumacaftor 100mg/ivacaftor 125mg

Holder

Parexel International

Status

Running

Indication

Treatment of cystic fibrosis (CF) in patients 6 through 11 years of age who are homozygous for the F508del mutation in the CFTR gene.

Public documents

Approbation

Information for the patient

Informed consent

Last update

21/08/2018

Last updated on 21/08/2018